GLP-1s are predicted to become the best-selling drug class of 2024 (inclusive of diabetes and obesity) 2 The late-stage obesity pipeline is dominated by big pharma, and 8 of the top 20 pharma companies have a clinical stage asset in development The obesity pipeline has almost tripled in size since June 2023, and there are up to 6 new U.S
Chronic hyperglycemia and hyperinsulinemia drive a metabolic imbalance promoting oxidative stress, inflammation, and endothelial damage, responsible for non-enzymatic biomolecule glycation, accelerating cerebrovascular atherosclerosis and neurodegenerative damage that further promote cognitive dysfunction and dementia (Kopp et al., 2022)
Any future clinical use should continue to be guided by physician judgment, patient-specific considerations, and applicable regulations
The test does not predict your exact medication response or guarantee how quickly you will reach therapeutic doses
Research shows that most adults who stop a GLP-1 medication regain at least some of their weight in the year after stopping the medication, with one study showing an average regain of two-thirds of their previous weight loss
The Warning Letters targeted mostly semaglutide, tirzepatide and retatrutide as well as other peptides such as BPC-157 and selective androgen receptor or anabolic steroids (SARMS) such as trendione